Company Profile

Acurex Therapeutics Corporation
Profile last edited on: 9/28/22      CAGE:       UEI: P28VVN78A333

Business Identifier: Halting neurodegeneration with disease altering therapeutics
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

930 Brittan Avenue
San Carlos, CA 94070
Location: Single
Congr. District: 14
County: San Mateo

Public Profile

AcureX Therapeutics is a pharmaceutical company structured around improving outcomes in the arenas of major neurodegenerative diseases driven by impaired mitophagy - with Parkinson’s disease (PD) the initial focus. Substantial body of evidence now supports that impairment of mitophagy - the normal process by which cells dispose of dysfunctional mitochondria - plays a significant role in the pathogenesis of PD and other diseases. ​AcureX’s platform and underpinning IP are based on a Stanford University breakthrough that is enabling identification of druggable targets responsible for defects in mitophagy. To date, AcureX’s platform has generated two oral small-molecule therapeutic programs that cross the BBB, reactivate mitophagy, and protect PD patient-derived neurons. AcureX’s lead program has begun IND-enabling studies, and the second program to a distinct target is shortly behind. In addition to PD, AcureX has demonstrated value for this approach in other diseases where mitophagy is implicated, opening future market opportunities beyond PD and neurodegeneration. ​ AcureX’s clinical development plan leverages its proprietary biomarker of mitophagy that can be measured in the periphery and is significantly altered in PD patients, including patients with LRRK2 and GBA PD. AcureX’s mitophagy biomarker changes with drug treatment, enabling early efficacy insights and de-risking in phase 1b rather than in phase 2b trials. AcureX's biomarker for pre-selection and stratification of patients combined with our drug treatment will be a significant step forward in bringing personalized medicine to treating CNS diseases. Supported by $5.5M from the Michael J. Fox Foundation for Parkinson’s Research, the Silverstein Foundation for Parkinson's with GBA, NIH grant funding and private funding. Contact Us Ac

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  William D Shrader -- Founder and CEO/CSO

Company News

There are no news available.